ELI LILLY & Co
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly COVID-19 Antibodies by Year
COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue YoY (%) [legacy] (%)
Eli Lilly COVID-19 Antibodies: -100.0% in FY2023, down 90.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
“|| COVID-19 antibodies (d) | — | 38.0 | (100)% | — | 2,023.5 | (100)%”
Source: Earnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue YoY (%) [legacy] (%) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | -100.0% | -90.0 pts | Earnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗ |
| FY2022 | Dec 31, 2022 | -10.0% | – | Form 10-K FY2022 (filed 2023-02-22) ↗ |
Cite this data
StockData. (2026). Eli Lilly COVID-19 Antibodies (%), annual FY2022–FY2023 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-covid19antibodies-yoy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.